Global Metabotropic Glutamate Receptor

Metabotropic Glutamate Receptor Comprehensive Study by Type (MGluR2 , MGluR4 , MGluR5), Application (Attention Deficit Hyperactivity Disorder , Alzheimer's Disease , Chronic Obstructive Pulmonary Disease) Players and Region - Global Market Outlook to 2028

Metabotropic Glutamate Receptor Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
The Metabotropic Glutamate Receptor market is expected to witness high demand due to the growing incidences of neurological disorders across the world. and metabotropic glutamate receptors or mGluRs (MGRs) are a form of glutamate receptors that are active through an indirect metabotropic process. They are members of the group C family of G-protein-coupled receptors or GPCRs. MGRs provide a novel target to develop therapeutic agents that are anticipated to have a dramatic impact on the treatment of a wide variety of psychiatric and neurologic disorders.

AttributesDetails
Study Period2018-2028
Base Year2022
High Growth MarketAsia Pacific
UnitValue (USD Million)
Key Companies ProfiledAddex Therapeutics Ltd (Switzerland), Domain Therapeutics SA (France), Medgenics (United States), Prexton Therapeutics SA (Netherlands), Taisho Pharmaceutical Holdings (Japan), Abcam plc (United Kingdom), AstraZeneca plc (United Kingdom), Novartis (Switzerland) and Eli Lilly and Company (United States)


This growth is primarily driven by The Increasing Prevalence of Neurological Diseases and Rising Disposable Income.

Globally, a noticeable market trend is evident The Surge in Global Geriatric Population The Biotechnology sector in the North America region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Addex Therapeutics Ltd (Switzerland), Domain Therapeutics SA (France), Medgenics (United States), Prexton Therapeutics SA (Netherlands), Taisho Pharmaceutical Holdings (Japan), Abcam plc (United Kingdom), AstraZeneca plc (United Kingdom), Novartis (Switzerland) and Eli Lilly and Company (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. Leading key players are focusing on strategic partnerships to improve their products and services. Companies are focusing on increasing their client base to strengthen their market position and enhance product & service offerings.

Key Developments in the Market:
In July 2022, AstraZeneca announced an agreement to acquire TeneoTwo, Inc., including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma1. The acquisition of TNB-486 aims to accelerate the development of this potential new medicine for B-cell hematologic malignancies.
Addex Therapeutics has been focusing on the discovery and development of orally available small molecules targeting mGluRs for the treatment of neurological disorders, such as Parkinson's disease.

Influencing Trend:
The Surge in Global Geriatric Population and The Growth in the R & D in Healthcare

Market Growth Drivers:
The Increasing Prevalence of Neurological Diseases and Rising Disposable Income

Challenges:
Stringent Government Regulations

Restraints:
The Growing Concern Regarding Lack of Awareness of MRGs

Opportunities:
The Growing Healthcare Expenditure in Developing Countries

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Metabotropic Glutamate Receptor Market
- Analysis about New Entrants in Metabotropic Glutamate Receptor Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Metabotropic Glutamate Receptor Study Sheds Light on
— The Metabotropic Glutamate Receptor Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Metabotropic Glutamate Receptor industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Metabotropic Glutamate Receptor industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • mGluR2 
  • mGluR4 
  • mGluR5
By Application
  • Attention Deficit Hyperactivity Disorder 
  • Alzheimer's Disease 
  • Chronic Obstructive Pulmonary Disease
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Increasing Prevalence of Neurological Diseases
      • 3.2.2. Rising Disposable Income
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Regulations
    • 3.4. Market Trends
      • 3.4.1. The Surge in Global Geriatric Population
      • 3.4.2. The Growth in the R & D in Healthcare
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Metabotropic Glutamate Receptor, by Type, Application and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Metabotropic Glutamate Receptor (Value)
      • 5.2.1. Global Metabotropic Glutamate Receptor by: Type (Value)
        • 5.2.1.1. MGluR2 
        • 5.2.1.2. MGluR4 
        • 5.2.1.3. MGluR5
      • 5.2.2. Global Metabotropic Glutamate Receptor by: Application (Value)
        • 5.2.2.1. Attention Deficit Hyperactivity Disorder 
        • 5.2.2.2. Alzheimer's Disease 
        • 5.2.2.3. Chronic Obstructive Pulmonary Disease
      • 5.2.3. Global Metabotropic Glutamate Receptor Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Metabotropic Glutamate Receptor: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Addex Therapeutics Ltd (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Domain Therapeutics SA (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Medgenics (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Prexton Therapeutics SA (Netherlands)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Taisho Pharmaceutical Holdings (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Abcam plc (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AstraZeneca plc (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eli Lilly and Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Metabotropic Glutamate Receptor Sale, by Type, Application and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Metabotropic Glutamate Receptor (Value)
      • 7.2.1. Global Metabotropic Glutamate Receptor by: Type (Value)
        • 7.2.1.1. MGluR2 
        • 7.2.1.2. MGluR4 
        • 7.2.1.3. MGluR5
      • 7.2.2. Global Metabotropic Glutamate Receptor by: Application (Value)
        • 7.2.2.1. Attention Deficit Hyperactivity Disorder 
        • 7.2.2.2. Alzheimer's Disease 
        • 7.2.2.3. Chronic Obstructive Pulmonary Disease
      • 7.2.3. Global Metabotropic Glutamate Receptor Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Metabotropic Glutamate Receptor: by Type(USD Million)
  • Table 2. Metabotropic Glutamate Receptor MGluR2  , by Region USD Million (2017-2022)
  • Table 3. Metabotropic Glutamate Receptor MGluR4  , by Region USD Million (2017-2022)
  • Table 4. Metabotropic Glutamate Receptor MGluR5 , by Region USD Million (2017-2022)
  • Table 5. Metabotropic Glutamate Receptor: by Application(USD Million)
  • Table 6. Metabotropic Glutamate Receptor Attention Deficit Hyperactivity Disorder  , by Region USD Million (2017-2022)
  • Table 7. Metabotropic Glutamate Receptor Alzheimer's Disease  , by Region USD Million (2017-2022)
  • Table 8. Metabotropic Glutamate Receptor Chronic Obstructive Pulmonary Disease , by Region USD Million (2017-2022)
  • Table 9. South America Metabotropic Glutamate Receptor, by Country USD Million (2017-2022)
  • Table 10. South America Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 11. South America Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 12. Brazil Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 13. Brazil Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 14. Argentina Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 15. Argentina Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 16. Rest of South America Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 17. Rest of South America Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 18. Asia Pacific Metabotropic Glutamate Receptor, by Country USD Million (2017-2022)
  • Table 19. Asia Pacific Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 20. Asia Pacific Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 21. China Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 22. China Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 23. Japan Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 24. Japan Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 25. India Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 26. India Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 27. South Korea Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 28. South Korea Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 29. Taiwan Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 30. Taiwan Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 31. Australia Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 32. Australia Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 33. Rest of Asia-Pacific Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 34. Rest of Asia-Pacific Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 35. Europe Metabotropic Glutamate Receptor, by Country USD Million (2017-2022)
  • Table 36. Europe Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 37. Europe Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 38. Germany Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 39. Germany Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 40. France Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 41. France Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 42. Italy Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 43. Italy Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 44. United Kingdom Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 45. United Kingdom Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 46. Netherlands Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 47. Netherlands Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 48. Rest of Europe Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 49. Rest of Europe Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 50. MEA Metabotropic Glutamate Receptor, by Country USD Million (2017-2022)
  • Table 51. MEA Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 52. MEA Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 53. Middle East Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 54. Middle East Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 55. Africa Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 56. Africa Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 57. North America Metabotropic Glutamate Receptor, by Country USD Million (2017-2022)
  • Table 58. North America Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 59. North America Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 60. United States Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 61. United States Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 62. Canada Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 63. Canada Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 64. Mexico Metabotropic Glutamate Receptor, by Type USD Million (2017-2022)
  • Table 65. Mexico Metabotropic Glutamate Receptor, by Application USD Million (2017-2022)
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Metabotropic Glutamate Receptor: by Type(USD Million)
  • Table 76. Metabotropic Glutamate Receptor MGluR2  , by Region USD Million (2023-2028)
  • Table 77. Metabotropic Glutamate Receptor MGluR4  , by Region USD Million (2023-2028)
  • Table 78. Metabotropic Glutamate Receptor MGluR5 , by Region USD Million (2023-2028)
  • Table 79. Metabotropic Glutamate Receptor: by Application(USD Million)
  • Table 80. Metabotropic Glutamate Receptor Attention Deficit Hyperactivity Disorder  , by Region USD Million (2023-2028)
  • Table 81. Metabotropic Glutamate Receptor Alzheimer's Disease  , by Region USD Million (2023-2028)
  • Table 82. Metabotropic Glutamate Receptor Chronic Obstructive Pulmonary Disease , by Region USD Million (2023-2028)
  • Table 83. South America Metabotropic Glutamate Receptor, by Country USD Million (2023-2028)
  • Table 84. South America Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 85. South America Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 86. Brazil Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 87. Brazil Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 88. Argentina Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 89. Argentina Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 90. Rest of South America Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 91. Rest of South America Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 92. Asia Pacific Metabotropic Glutamate Receptor, by Country USD Million (2023-2028)
  • Table 93. Asia Pacific Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 94. Asia Pacific Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 95. China Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 96. China Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 97. Japan Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 98. Japan Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 99. India Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 100. India Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 101. South Korea Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 102. South Korea Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 103. Taiwan Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 104. Taiwan Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 105. Australia Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 106. Australia Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 107. Rest of Asia-Pacific Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 108. Rest of Asia-Pacific Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 109. Europe Metabotropic Glutamate Receptor, by Country USD Million (2023-2028)
  • Table 110. Europe Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 111. Europe Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 112. Germany Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 113. Germany Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 114. France Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 115. France Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 116. Italy Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 117. Italy Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 118. United Kingdom Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 119. United Kingdom Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 120. Netherlands Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 121. Netherlands Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 122. Rest of Europe Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 123. Rest of Europe Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 124. MEA Metabotropic Glutamate Receptor, by Country USD Million (2023-2028)
  • Table 125. MEA Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 126. MEA Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 127. Middle East Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 128. Middle East Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 129. Africa Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 130. Africa Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 131. North America Metabotropic Glutamate Receptor, by Country USD Million (2023-2028)
  • Table 132. North America Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 133. North America Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 134. United States Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 135. United States Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 136. Canada Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 137. Canada Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 138. Mexico Metabotropic Glutamate Receptor, by Type USD Million (2023-2028)
  • Table 139. Mexico Metabotropic Glutamate Receptor, by Application USD Million (2023-2028)
  • Table 140. Research Programs/Design for This Report
  • Table 141. Key Data Information from Secondary Sources
  • Table 142. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Metabotropic Glutamate Receptor: by Type USD Million (2017-2022)
  • Figure 5. Global Metabotropic Glutamate Receptor: by Application USD Million (2017-2022)
  • Figure 6. South America Metabotropic Glutamate Receptor Share (%), by Country
  • Figure 7. Asia Pacific Metabotropic Glutamate Receptor Share (%), by Country
  • Figure 8. Europe Metabotropic Glutamate Receptor Share (%), by Country
  • Figure 9. MEA Metabotropic Glutamate Receptor Share (%), by Country
  • Figure 10. North America Metabotropic Glutamate Receptor Share (%), by Country
  • Figure 11. Global Metabotropic Glutamate Receptor share by Players 2022 (%)
  • Figure 12. Global Metabotropic Glutamate Receptor share by Players (Top 3) 2022(%)
  • Figure 13. Global Metabotropic Glutamate Receptor share by Players (Top 5) 2022(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Addex Therapeutics Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 16. Addex Therapeutics Ltd (Switzerland) Revenue: by Geography 2022
  • Figure 17. Domain Therapeutics SA (France) Revenue, Net Income and Gross profit
  • Figure 18. Domain Therapeutics SA (France) Revenue: by Geography 2022
  • Figure 19. Medgenics (United States) Revenue, Net Income and Gross profit
  • Figure 20. Medgenics (United States) Revenue: by Geography 2022
  • Figure 21. Prexton Therapeutics SA (Netherlands) Revenue, Net Income and Gross profit
  • Figure 22. Prexton Therapeutics SA (Netherlands) Revenue: by Geography 2022
  • Figure 23. Taisho Pharmaceutical Holdings (Japan) Revenue, Net Income and Gross profit
  • Figure 24. Taisho Pharmaceutical Holdings (Japan) Revenue: by Geography 2022
  • Figure 25. Abcam plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. Abcam plc (United Kingdom) Revenue: by Geography 2022
  • Figure 27. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. AstraZeneca plc (United Kingdom) Revenue: by Geography 2022
  • Figure 29. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Novartis (Switzerland) Revenue: by Geography 2022
  • Figure 31. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 32. Eli Lilly and Company (United States) Revenue: by Geography 2022
  • Figure 33. Global Metabotropic Glutamate Receptor: by Type USD Million (2023-2028)
  • Figure 34. Global Metabotropic Glutamate Receptor: by Application USD Million (2023-2028)
  • Figure 35. South America Metabotropic Glutamate Receptor Share (%), by Country
  • Figure 36. Asia Pacific Metabotropic Glutamate Receptor Share (%), by Country
  • Figure 37. Europe Metabotropic Glutamate Receptor Share (%), by Country
  • Figure 38. MEA Metabotropic Glutamate Receptor Share (%), by Country
  • Figure 39. North America Metabotropic Glutamate Receptor Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Addex Therapeutics Ltd (Switzerland)
  • Domain Therapeutics SA (France)
  • Medgenics (United States)
  • Prexton Therapeutics SA (Netherlands)
  • Taisho Pharmaceutical Holdings (Japan)
  • Abcam plc (United Kingdom)
  • AstraZeneca plc (United Kingdom)
  • Novartis (Switzerland)
  • Eli Lilly and Company (United States)
Select User Access Type

Key Highlights of Report


May 2023 235 Pages 95 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Metabotropic Glutamate Receptor Quantitative research analysis
Global Metabotropic Glutamate Receptor Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Metabotropic Glutamate Receptor market are Addex Therapeutics Ltd (Switzerland), Domain Therapeutics SA (France), Medgenics (United States), Prexton Therapeutics SA (Netherlands), Taisho Pharmaceutical Holdings (Japan), Abcam plc (United Kingdom), AstraZeneca plc (United Kingdom), Novartis (Switzerland) and Eli Lilly and Company (United States), to name a few.
North America is dominating the Metabotropic Glutamate Receptor Market.
"Stringent Government Regulations" is seen as one of the major challenges by many Industry Players of Metabotropic Glutamate Receptor Market
The Metabotropic Glutamate Receptor market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Metabotropic Glutamate Receptor market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Metabotropic Glutamate Receptor Report?

Have a Query? Click Here

Other Related Reports

Protective Cultures Comprehensive Study by Type (Pure Culture, Mixed Culture), Application (Dairy Based Products, Meat & poultry Products, Seafood, Bakery & Confectioneries, RTE Food Products, Bevera...
$ 3650
Biophotonics Comprehensive Study by Type (Single Photon Source, Lasers, LEDs, Lamps, Others), Application (Biotechnology, Medicine, Environmental technology, Agricultural sciences, Chemical and pharm...
$ 3750
Composite Artificial Skin Comprehensive Study by Type (Skin Graft, Engineered Skin Material), Application (Human Treatment, Robots, Research, Others), Components (Epidermal Skin, Dermal Skin), End Us...
$ 3450
Electrocompetent Cells Comprehensive Study by Type (Cloned Competent Cells, Agrobacterium tumefaciens Competent Cells, Expression Competent Cells), Application (Subcloning & Routine Cloning, Phage Di...
$ 3750
Chemically Competent Cells Comprehensive Study by Type (Cloned Competent Cells, Electro-competent Cells, Agrobacterium tumefaciens Competent Cells, Expression Competent Cells), Application (Cloning, ...
$ 3650
Cell Separation Technologies Comprehensive Study by Type (Gradient Centrifugation, Surface Markers Separation (Fluorescence-activated cell sorting (FACS), Magnetic-Activated Cell Sorting (MACS), Filt...
$ 3750